《半日总结》恒指升178点 阿里破顶 联通中电讯扬逾7%
市场憧憬美国白宫与国会就新一轮刺激经济方案取得共识，美股昨日(20日)造好，亚太区股市承接升势，港股早市亦向上。恒指高开126点，早段升幅曾扩大至333点一度高见24,903点，其後内地股市倒跌，港股升幅收窄。恒指半日升178点或0.7%，报24,747点；国指升76点或0.8%，报10,064点；恒生科技指数升12点或0.2%，报7,657点。大市半日成交总额610.86亿元，沪，深港通南下交易半日录得净流入金额分别为11.45亿及12.11亿元人民币。
蓝筹股方面，腾讯(00700.HK)升0.1%报565元，盘中高见573元。阿里巴巴(09988.HK)升0.5%报301元，盘中见303.8元新高。小米(01810.HK)升2.5%报22.75元。汇控(00005.HK)升0.5%报30.95元，港交所(00388.HK)升1.4%报372.2元，友邦(01299.HK)跌0.1%报77.9元。内银股建行(00939.HK)及工行(01398.HK)各升1.4%及1.5%。国指成分股招行(03968.HK)及民行(01988.HK)各升2.5%及2.1%。
中移动(00941.HK)第三季末5G套餐客户总数达到1.14亿户，提早完成今年原定上客目标。中移动升2%报50.95元，中电信(00728.HK)及联通(00762.HK)各升7.1%及7.4%。
国泰(00293.HK)公布重组计划结束国泰港龙业务及大幅裁员，股价升4%报5.95元。太古A(00019.HK)跌0.4%报37.6元；国航(00753.HK)早市股价上升1.2%收5.22元。
多间券商引述药明生物(02269.HK)管理层表示，预计下半年收入将年增长40%及明年收入料增长50%，药明生物股价弹11.6%报225元。其他医药股方面，信达生物(01801.HK)及国药(01099.HK)各升5.5%及3%。
其他科技股方面，美团(03690.HK)升2.8%报268元，京东(09618.HK)升2.2%报324.6元，网易(09999.HK)跌0.4%。手机相关股回软，比亚迪电子(00285.HK)及丘钛科技(01478.HK)各跌2.7%及2.2%。晶片股中芯(00981.HK)跌1%。
汽车股个别发展，东风(00489.HK)及广汽(02238.HK)各升1.9%及1.8%，北汽(01958.HK)升2.8%，比亚迪(01211.HK)则跌1.9%。内需股方面，维达(03331.HK)及高鑫零售(06808.HK)各跌2%及2.5%，康师傅(00322.HK)升2.4%。体育用品股李宁(02331.HK)升2.1%报41.55元，盘中见41.95元新高。
金银股受捧，中国黄金国际(02099.HK)升15.6%，招金(01818.HK)及中国白银(00815.HK)各升5.8%及4.1%，山东黄金(01787.HK)及紫金(02899.HK)各升2.8%及2.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
